Biolase Stock Probability Of Bankruptcy
| BIOL Stock | USD 0.14 0.01 6.67% |
BIOLASE | Probability Of Bankruptcy |
BIOLASE Company odds of financial distress Analysis
BIOLASE's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current BIOLASE Probability Of Bankruptcy | Over 83% |
Most of BIOLASE's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BIOLASE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of BIOLASE probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting BIOLASE odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of BIOLASE financial health.
Is BIOLASE's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BIOLASE. If investors know BIOLASE will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BIOLASE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (29.44) | Revenue Per Share 38.469 | Quarterly Revenue Growth (0.04) | Return On Assets (0.29) | Return On Equity (6.03) |
The market value of BIOLASE is measured differently than its book value, which is the value of BIOLASE that is recorded on the company's balance sheet. Investors also form their own opinion of BIOLASE's value that differs from its market value or its book value, called intrinsic value, which is BIOLASE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BIOLASE's market value can be influenced by many factors that don't directly affect BIOLASE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BIOLASE's value and its price as these two are different measures arrived at by different means. Investors typically determine if BIOLASE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BIOLASE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BIOLASE Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for BIOLASE is extremely important. It helps to project a fair market value of BIOLASE Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since BIOLASE's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BIOLASE's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BIOLASE's interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, BIOLASE has a Probability Of Bankruptcy of 83%. This is 91.73% higher than that of the Health Care Equipment & Supplies sector and 101.6% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 108.39% lower than that of the firm.
BIOLASE Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BIOLASE's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BIOLASE could also be used in its relative valuation, which is a method of valuing BIOLASE by comparing valuation metrics of similar companies.BIOLASE is currently under evaluation in probability of bankruptcy category among related companies.
BIOLASE Main Bankruptcy Drivers
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Asset Turnover | 1.2 | 1.19 | 0.56 | 0.71 | 1.27 | 1.4 | |
| Net Debt | 7.7M | 396K | (14.9M) | 10.9M | 11.3M | 11.9M | |
| Total Current Liabilities | 25.8M | 11.2M | 13.8M | 17.8M | 19.7M | 14.3M | |
| Non Current Liabilities Total | 5.7M | 19.8M | 16.2M | 15.5M | 15.7M | 16.5M | |
| Total Assets | 31.8M | 41.0M | 55.3M | 38.2M | 35.1M | 31.3M | |
| Total Current Assets | 27.0M | 35.1M | 49.4M | 29.0M | 24.9M | 25.5M | |
| Total Cash From Operating Activities | (12.7M) | (12.8M) | (16.7M) | (26.8M) | (14.1M) | (13.4M) |
BIOLASE Fundamentals
| Return On Equity | -6.03 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (0.42) % | ||||
| Operating Margin | (0.35) % | ||||
| Current Valuation | 15.77 M | ||||
| Shares Outstanding | 33.26 M | ||||
| Shares Owned By Insiders | 0.33 % | ||||
| Shares Owned By Institutions | 8.23 % | ||||
| Number Of Shares Shorted | 2.29 M | ||||
| Price To Earning | (7.23) X | ||||
| Price To Book | 0.77 X | ||||
| Price To Sales | 0.1 X | ||||
| Revenue | 49.16 M | ||||
| Gross Profit | 16.53 M | ||||
| EBITDA | (15.14 M) | ||||
| Net Income | (20.63 M) | ||||
| Cash And Equivalents | 9.96 M | ||||
| Cash Per Share | 1.39 X | ||||
| Total Debt | 17.91 M | ||||
| Debt To Equity | 1.07 % | ||||
| Current Ratio | 2.46 X | ||||
| Book Value Per Share | (0.07) X | ||||
| Cash Flow From Operations | (14.09 M) | ||||
| Short Ratio | 0.21 X | ||||
| Earnings Per Share | (29.44) X | ||||
| Price To Earnings To Growth | (0.22) X | ||||
| Target Price | 11.22 | ||||
| Number Of Employees | 157 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 4.52 M | ||||
| Total Asset | 35.1 M | ||||
| Retained Earnings | (316.8 M) | ||||
| Working Capital | 5.2 M | ||||
| Current Asset | 34.8 M | ||||
| Current Liabilities | 15.11 M | ||||
| Net Asset | 35.1 M |
About BIOLASE Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BIOLASE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BIOLASE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BIOLASE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BIOLASE in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BIOLASE's short interest history, or implied volatility extrapolated from BIOLASE options trading.
Pair Trading with BIOLASE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BIOLASE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BIOLASE will appreciate offsetting losses from the drop in the long position's value.Moving against BIOLASE Stock
| 0.87 | DVA | DaVita HealthCare Financial Report 13th of May 2024 | PairCorr |
| 0.8 | ENSG | Ensign Group Financial Report 24th of April 2024 | PairCorr |
| 0.76 | ISRG | Intuitive Surgical Earnings Call This Week | PairCorr |
| 0.73 | ICUI | ICU Medical Financial Report 13th of May 2024 | PairCorr |
| 0.71 | PNTG | Pennant Group Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to BIOLASE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BIOLASE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BIOLASE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BIOLASE to buy it.
The correlation of BIOLASE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BIOLASE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BIOLASE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BIOLASE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out BIOLASE Piotroski F Score and BIOLASE Altman Z Score analysis. For more information on how to buy BIOLASE Stock please use our How to buy in BIOLASE Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for BIOLASE Stock analysis
When running BIOLASE's price analysis, check to measure BIOLASE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BIOLASE is operating at the current time. Most of BIOLASE's value examination focuses on studying past and present price action to predict the probability of BIOLASE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BIOLASE's price. Additionally, you may evaluate how the addition of BIOLASE to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is BIOLASE's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BIOLASE. If investors know BIOLASE will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BIOLASE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (29.44) | Revenue Per Share 38.469 | Quarterly Revenue Growth (0.04) | Return On Assets (0.29) | Return On Equity (6.03) |
The market value of BIOLASE is measured differently than its book value, which is the value of BIOLASE that is recorded on the company's balance sheet. Investors also form their own opinion of BIOLASE's value that differs from its market value or its book value, called intrinsic value, which is BIOLASE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BIOLASE's market value can be influenced by many factors that don't directly affect BIOLASE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BIOLASE's value and its price as these two are different measures arrived at by different means. Investors typically determine if BIOLASE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BIOLASE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.